oral time-limited duvelisib/venetoclax in r/r cll
Published 4 years ago • 96 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
1:17
optimizing initial therapy in cll: time-limited, all-oral approaches
-
3:13
selection for time-limited & continuous therapy in cll
-
1:34
time-limited vs continuous therapy in cll treatment
-
1:24
omniverse: safety and tolerability of oral azacitidine plus venetoclax in patients with aml
-
2:04
time-limited venetoclax-rituximab in r/r cll patients previously exposed to btki’s
-
4:38
venice i: venetoclax in r/r cll patients
-
0:45
oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with aml
-
2:08
the role of venetoclax in the treatment of cll
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
5:52
the power of venetoclax
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll
-
1:24
time-limited therapy in cll
-
2:59
clinical trial updates and time-limited therapy in cll
-
2:50
gaia/cll13: venetoclax-based time-limited combination therapies in cll
-
0:49
considering patient preference when selecting between continuous and time-limited therapy in cll
-
1:29
the importance of treatment sequencing in cll
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:46
treating relapsed/refractory cll with venetoclax
-
3:35
an insight into time-limited therapy in cll
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
1:21
treating cll with venetoclax
-
5:20
advances in the use of bispecific antibodies for the treatment of cll